224 related articles for article (PubMed ID: 27207443)
21. Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.
Deng F; Chen J; Zheng J; Chen Y; Huang R; Yin J; Gao X; Lin Q; Huang C; Gao Y; Yu X; Liu Z
Int J Rheum Dis; 2016 Jul; 19(7):715-20. PubMed ID: 25941062
[TBL] [Abstract][Full Text] [Related]
22. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren's syndrome.
Kwok SK; Cho ML; Her YM; Oh HJ; Park MK; Lee SY; Woo YJ; Ju JH; Park KS; Kim HY; Park SH
Arthritis Res Ther; 2012 Mar; 14(2):R64. PubMed ID: 22417709
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome.
Vosters JL; Landek-Salgado MA; Yin H; Swaim WD; Kimura H; Tak PP; Caturegli P; Chiorini JA
Arthritis Rheum; 2009 Dec; 60(12):3633-41. PubMed ID: 19950301
[TBL] [Abstract][Full Text] [Related]
24. IL-2 Inhibition of Th17 Generation Rather Than Induction of Treg Cells Is Impaired in Primary Sjögren's Syndrome Patients.
Luo J; Ming B; Zhang C; Deng X; Li P; Wei Z; Xia Y; Jiang K; Ye H; Ma W; Liu Z; Li H; Yang XP; Dong L
Front Immunol; 2018; 9():1755. PubMed ID: 30150979
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
Park E; Kim D; Lee SM; Jun HS
Oncotarget; 2017 Apr; 8(16):27240-27251. PubMed ID: 28460477
[TBL] [Abstract][Full Text] [Related]
26. The role of RORα in salivary gland lesions in patients with primary Sjögren's syndrome.
Weng X; Liu Y; Cui S; Cheng B
Arthritis Res Ther; 2018 Sep; 20(1):205. PubMed ID: 30189901
[TBL] [Abstract][Full Text] [Related]
27. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
[TBL] [Abstract][Full Text] [Related]
28. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome.
Kurimoto C; Kawano S; Tsuji G; Hatachi S; Jikimoto T; Sugiyama D; Kasagi S; Komori T; Nakamura H; Yodoi J; Kumagai S
J Rheumatol; 2007 Oct; 34(10):2035-43. PubMed ID: 17896802
[TBL] [Abstract][Full Text] [Related]
29. A role for lymphotoxin in primary Sjogren's disease.
Shen L; Suresh L; Wu J; Xuan J; Li H; Zhang C; Pankewycz O; Ambrus JL
J Immunol; 2010 Nov; 185(10):6355-63. PubMed ID: 20952683
[TBL] [Abstract][Full Text] [Related]
30. Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.
Ciccia F; Guggino G; Rizzo A; Bombardieri M; Raimondo S; Carubbi F; Cannizzaro A; Sireci G; Dieli F; Campisi G; Giacomelli R; Cipriani P; De Leo G; Alessandro R; Triolo G
Clin Exp Immunol; 2015 Aug; 181(2):219-29. PubMed ID: 25880879
[TBL] [Abstract][Full Text] [Related]
31. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
Ciccia F; Guggino G; Rizzo A; Alessandro R; Carubbi F; Giardina A; Cipriani P; Ferrante A; Cannizzaro A; Giacomelli R; Triolo G
Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
[TBL] [Abstract][Full Text] [Related]
32. Fas (APO-1/CD95)-assisted suicide in NOD exocrine glands.
Elkon KB
Clin Exp Rheumatol; 1998; 16(6):659-61. PubMed ID: 9844755
[No Abstract] [Full Text] [Related]
33. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
[TBL] [Abstract][Full Text] [Related]
34. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors.
Bacman SR; Berra A; Sterin-Borda L; Borda ES
Curr Eye Res; 1998 Dec; 17(12):1135-42. PubMed ID: 9872535
[TBL] [Abstract][Full Text] [Related]
35. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.
Katsifis GE; Rekka S; Moutsopoulos NM; Pillemer S; Wahl SM
Am J Pathol; 2009 Sep; 175(3):1167-77. PubMed ID: 19700754
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome.
Vartoukian SR; Tilakaratne WM; Seoudi N; Bombardieri M; Bergmeier L; Tappuni AR; Fortune F
Clin Exp Immunol; 2014 Sep; 177(3):618-29. PubMed ID: 24827536
[TBL] [Abstract][Full Text] [Related]
37. The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjögren's syndrome.
Boras VV; Cikes N; Lukac J; Cekić-Arambasin A; Virag M; Bosnjak A
Coll Antropol; 2004; 28 Suppl 2():305-9. PubMed ID: 15571105
[TBL] [Abstract][Full Text] [Related]
38. Phagocyte-specific S100A8/A9 is upregulated in primary Sjögren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
Nicaise C; Weichselbaum L; Schandene L; Gangji V; Dehavay F; Bouchat J; Balau B; Vogl T; Soyfoo MS
Clin Exp Rheumatol; 2017; 35(1):129-136. PubMed ID: 27749214
[TBL] [Abstract][Full Text] [Related]
39. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren's syndrome.
Beroukas D; Hiscock J; Jonsson R; Waterman SA; Gordon TP
Lancet; 2001 Dec; 358(9296):1875-6. PubMed ID: 11741631
[TBL] [Abstract][Full Text] [Related]
40. Quantitative and visual evaluation of salivary and thyroid glands in patients with primary Sjögren's syndrome using salivary gland scintigraphy: relationship with clinicopathological features of salivary, lacrimal and thyroid glands.
Güne S; Yilmaz S; Karalezli A; Aktaş A
Nucl Med Commun; 2010 Jul; 31(7):666-72. PubMed ID: 20545046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
